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Objective: Along with the increasing prevalence of obesity and related diseases, particularly atherosclerotic diseases, metabolic
syndrome (MetS) is now a common and major public health issue in many countries around the world. Adiponectin, a protein
secreted by the adipose tissue, has become recognized as a key player in the development of MetS. These days, not only MetS
but also borderline metabolic/physiological abnormalities, such as impaired fasting glucose, high normal blood pressure and
high normal plasma cholesterol, have been reported to be risk factors for atherosclerotic disease. Therefore, we undertook this
study to determine the relationship between adiponectin and borderline metabolic/physiological abnormalities, as well as MetS.
Design: A cross-sectional study performed from April 2007 to November 2009.
Subjects: In 16892 Japanese adults (10008 men and 6884 women), we examined the relationship between the serum
adiponectin concentration and borderline metabolic/physiological abnormalities or MetS by a questionnaire survey about
medical treatment, body size measurement and measurement of laboratory parameters including the serum adiponectin
concentration.
Results: Adiponectin showed a significant negative correlation with the number of MetS components. In subjects without overt
diabetes mellitus, hypertension or dyslipidemia, the adiponectin concentration also showed a significant negative correlation
with the number of borderline metabolic abnormalities.
Conclusion: The decrease of circulating adiponectin may start before the development of diabetes mellitus, hypertension,
dyslipidemia or MetS. Adiponectin is an important biomarker for reflecting the adverse influence of visceral fat in persons with
MetS, and also in these subclinical states.
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Introduction
In recent years, the increased prevalence of obesity has led to
an increase of related diseases, especially atherosclerotic
diseases such as cardiovascular and cerebrovascular disease,
which are now responsible for high levels of morbidity and
mortality.
1 Many of these patients have metabolic syndrome
(MetS), which arises from the accumulation of visceral fat.
2
Thus, MetS has become a major public health issue in many
countries around the world.
To identify the molecular mechanisms underlying diseases
related to visceral obesity, the biological characteristics of the
adipose tissue were investigated by analysis of the gene
expression profile in fat, and revealed a gene named
adiponectin.
3 Adiponectin is found at a relatively high
concentration in human plasma, accounting for approxi-
mately 0.01% of total plasma protein,
4 and its level is
inversely correlated with visceral adiposity.
5 Many studies
have been performed on adiponectin and various compo-
nents of the MetS. As a result, adiponectin has been reported
to exhibit insulin-sensitizing, antiatherogenic and antiin-
flammatory effects.
6,7 Conversely, low adiponectin levels are
related to insulin resistance, an increased risk of type 2
diabetes,
8 hypertension,
9 dyslipidemia
10 and low plasma
levels of high-density lipoprotein cholesterol.
10 Because of
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and the regulation of adiponectin might be considered as an
efficient therapeutic procedure.
2,12
Several borderline metabolic and physiological abnormal-
ities, such as impaired fasting glucose, high normal blood
pressure (BP) and a high normal plasma level of low-density
lipoprotein cholesterol, have also been reported to increase
the risk of atherosclerotic disease.
13–17 However, there have
been no studies of adiponectin levels in such subclinical
populations. Therefore, we undertook this study to deter-
mine the relationship between adiponectin and borderline
metabolic/physiological abnormalities, as well as MetS.
Subjects and methods
The subjects of this study were 16892 adults (10008 men
and 6884 women) who had complete medical checkup at the
Physical Check up Center in Sumitomo Hospital from April
2007 to November 2009. In Japan, people often had their
medical checkup by their own will at a physical checkup
center attached to some hospitals, in order to evaluate their
health condition. The subjects of this study were those who
were not patients visited to our hospital, and all of them had
no apparent disease that required hospital admission. A
questionnaire about medical treatment was completed,
followed by the measurement of body size and blood tests
(including the serum adiponectin concentration). BP was
measured while they are sitting. All people who received
medication of diabetes mellitus, hypertension and dyslipi-
demia were excluded. All participants signed informed
consent to provide medical information and blood samples
before undergoing the medical check up, and they had the
right to refuse use of their data. The ethical committee
of Sumitomo Hospital approved this study and it was
conducted according to the principles of the Declaration of
Helsinki.
MetS was diagnosed according to the Japanese criteria,
18
which are a waist circumference of at least 85cm for men or
90cm for women and at least two of the following: glucose
intolerance (fasting plasma glucoseX110mgdl
 1), high BP
(systolic/diastolic BPX130/85mmHg) and dyslipidemia
(triglyceridesX150mgdL
 1 and high-density lipoprotein
cholesterolo40mgdl
 1). Borderline metabolic abnormal-
ities were defined as follows: impaired fasting glycemia was
fasting plasma glucose of 110–125mgdl
 1, high normal BP
was a systolic BP of 130–139mmHg and/or diastolic BP of
85–89mmHg, and high normal low-density lipoprotein
cholesterol was an low-density lipoprotein cholesterol of
120–139mgdl
 1, according to the criteria of the Japan
Diabetes Society,
19 Japanese Society of Hypertension
20 and
Japan Atherosclerosis Society,
21 respectively. Diagnosis of
diabetes mellitus (fasting plasma glucoseX126mgdl
 1 or
hemoglobin A1c (HbA1c) X6.5%(National Glycohemoglobin
Standardization Program)), hypertension (systolic BPX
140mmHg or diastolic BPX90mmHg) and dyslipidemia
(low-density lipoprotein cholesterolX140, triglyceri-
desX150 and high-density lipoprotein cholesterolo40) was
also done according to the criteria of these three societies.
The serum adiponectin level was used to divide the
subjects into five groups, which were less than 4mgml
 1
(hypoadiponectinemia),
22 more than 4mgml
 1 and less than
7mgml
 1, more than 7mgml
 1 and less than 10mgml
 1,
more than 10mgml
 1 and less than 13mgml
 1 and more
than 13mgml
 1. Then the relationship between the adipo-
nectin level and the number of MetS components, the
presence/absence of borderline metabolic abnormalities and
the waist circumference was examined. When investigating
the number of borderline metabolic abnormalities, patients
with clinically overt conditions such as diabetes, hyperten-
sion or dyslipidemia (5937 men and 2215 women) were
excluded.
The serum adiponectin level was measured by a latex
particle-enhanced turbidimeric immunoassay (Human adi-
ponectin latex kit, Otsuka Pharmaceutical Co. Ltd, Tokyo,
Japan) as reported previously.
23 HbAlc (%) was converted to a
National Glycohemoglobin Standardization Program
(National Glycohemoglobin Standardization Program)
equivalent value (%) by the formula HbA1c (National
Glycohemoglobin Standardization Program) (%)¼HbA1c
(Japan Diabetes Society) (%)þ0.4%, based on the relation-
ship previously determined between HbA1c (Japan Diabetes
Society) (%) measured with the previous Japanese standard
substance and measurement method and HbA1c (National
Glycohemoglobin Standardization Program).
19
Statistical analysis was performed with Windows-based
SPSS software (version 19.0, SPSS, Chicago, IL, USA). Non-
normally distributed variables were log transformed before
the analysis. Descriptive statistics were determined and the
student’s t-test or w
2-test was conducted for comparison
between MetS and non-MetS subjects among men and
among women separately. One-way analysis of variance
was performed to compare continuous variables. Post-hoc
multiple comparisons were made by using Tukey’s test.
Multiple linear regression analysis was employed to examine
the relationship between the number of MetS components or
high normal states and variables listed in Table 1 except for
the marker of diabetes mellitus, hypertension, dyslipidemia
and waist circumference. Statistical significance was
accepted at Po0.05.
Results
Clinical and biological characteristics
The clinical and biological characteristics of the participants
are shown in Table 1. On average, subjects without MetS
were younger, had a smaller body mass index and waist
circumference than those with MetS both in men and
women. They also had a lower BP, fasting plasma glucose,
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resistance and uric acid than the subjects with MetS, as well
as a better lipid profile both in men and women. The mean
serum adiponectin concentration was higher in people
without MetS than those with MetS, being 8.3 vs 6.2mgml
 1
in men and 13.3 vs 9.3mgml
 1 in women, respectively
(Po0.001).
One-way analysis of variance
Adiponectin showed a significant negative correlation with
the number of MetS components (Figure 1), the number of
borderline metabolic abnormalities (Figure 2) and the waist
circumference (Figure 3).
Multivariable analysis
According to multivariate analysis, the serum adiponectin
concentration was negatively correlated with the number of
MetS components (Table 2). Body mass index, age, HOMA-R,
uric acid and smoking habit showed a significant positive
correlation with the number of MetS components, and sex
(female) and creatinine showed a significant negative
correlation with them. Similarly, after excluding the patients
Table 1 Clinical and biological characteristics of participants
Men (n¼10008) P
a Women (n¼6884) P
a
Non-MetS (n¼8722) MetS (n¼1286) Non-MetS (n¼6799) MetS (n¼85)
Age (year) 51.3±11.0 52.4±10.0 o0.001 48.7±10.9 56.2±10.7 o0.001
Height (cm) 170.3±6.0 171.7±6.0 o0.001 158.2±5.5 156.8±5.3 0.016
Body weight (kg) 66.6±9.0 77.5±9.9 o0.001 51.8±7.3 69.2±12.7 o0.001
BMI (kgm
 2) 22.9±2.7 26.3±2.9 o0.001 20.7±2.8 28.1±4.4 o0.001
Waist (cm) 83.7±7.4 93.5±6.4 o0.001 76.5±8.2 97.8±7.4 o0.001
Smoking (no/yes) 5935/2787 825/461 0.007 6253/546 73/12 0.041
Systolic BP (mmHg) 122.7±14.0 138.0±12.5 o0.001 117.1±15.3 144.8±14.7 o0.001
Diastolic BP (mmHg) 77.2±9.5 87.0±8.6 o0.001 72.5±9.9 87.9±9.4 o0.001
T-CHO (mgdl
 1) 210.4±32.1 223.2±33.4 o0.001 215.1±36.0 245.3±43.2 o0.001
LDL-C (mgdl
 1) 126.4±30.5 136.7±32.0 o0.001 118.8±31.6 154.1±38.6 o0.001
HDL-C (mgdl
 1) 60.0±13.9 52.5±11.1 o0.001 73.1±16.3 58.7±13.9 o0.001
TG (mgdl
 1) 122.6±85.2 219.9±124.8 o0.001 83.2±46.5 192.3±81.4 o0.001
FPG (mgdl
 1) 94.1±12.9 108.9±25.5 o0.001 88.0±9.2 112.1±38.8 o0.001
HbA1c (NGSP) (%) 5.6±0.5 6.0±0.9 o0.001 5.4±0.4 6.1±1.3 o0.001
HOMA-IR 1.3±0.8 2.6±2.0 o0.001 1.1±0.6 3.2±2.4 o0.001
Uric acid (mgdl
 1)6 . 1 ±1.2 6.6±1.2 o0.001 4.4±0.9 5.5±1.0 o0.001
Cr (mgdl
 1) 0.83±0.20 0.82±0.12 0.253 0.61±0.10 0.58±0.09 0.001
Adiponectin (mgml
 1)8 . 3 ±4.2 6.2±2.8 o0.001 13.3±6.0 9.3±4.8 o0.001
Abbreviations: BMI, body mass index; BP, blood pressure; Cr, serum creatinine; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; HbA1c,
hemoglobin A1c; LDL-C, low-density lipoprotein cholesterol; NGSP, National Glycohemoglobin Standardization Program; T-CHO, total cholesterol;
TG, triglycerides; HOMA-IR, homeostasis model assessment-insulin resistance. Waist, waist circumference. Values are expressed as mean±standard deviations.
aStudent’s t-test or w
2-test at Po0.05.
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Figure 1 The number of MetS components in relation to the serum
adiponectin level. Gray bars (left) show the number of MetS components in
men and black bars (right) show the number in women.
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The number of borderline metabolic/physiological
abnormalities and adiponectin
Figure 2 The number of borderline metabolic/physiological abnormalities in
relation to the serum adiponectin level among subjects without diabetes,
hypertension or dyslipidemia. Gray bars (left) show the number of borderline
abnormalities in men and black bars (right) show the number in women.
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the serum adiponectin concentration was negatively corre-
lated with the number of borderline metabolic abnormalities
(Table 3). Body mass index, age, HOMA-R and uric acid also
showed a significant positive correlation with the number
of high normal states, and smoking habit, sex (female)
and creatinine showed a significant negative correlation
with them.
Discussion
MetS is now well known to be a risk factor for the
cardiovascular and cerebrovascular disease, and many
studies have demonstrated an association between serum
adiponectin levels and MetS. In recent years, borderline
metabolic/physiological abnormalities, such as impaired
fasting glucose, high normal BP and high normal plasma
LDL cholesterol, have also been reported to be the risk
factors for atherosclerotic disease. However, there has been
no investigation of the relationship between the serum
adiponectin level and such high normal states. Accordingly,
this is the first large-scale investigation of the relationship
between adiponectin and borderline metabolic/physiological
abnormalities.
The present study revealed several important findings.
First, it confirmed a significant negative correlation between
adiponectin and the number of MetS components, as
previously reported.
24 Second, this study also showed a
significant negative correlation between adiponectin and the
number of borderline metabolic/physioligical abnormalities
in a population from which overt diabetes, hypertension and
dyslipidemia had been excluded. Although the association
was not significant in women from the lowest adiponectin
group (Figure 2), this was probably due to the small number
of women in the hypoadiponectinemia group (n¼53).
Third, the adiponectin level decreased significantly as the
waist circumference increased. Though waist circumference
is not the optimal measure of visceral fat, this result shows
the association between serum adiponectin level and the
amount of visceral fat, as it has been reported.
2
The decrease of adiopnectin is mainly caused by the
accumulation of visceral fat, as well as genetic character-
istics, and the present study showed that adiponectin starts
to decline and its lack has adverse effects even in people with
borderline metabolic/physiological abnormalities. It has
been already reported that the adiponectin level is decreased
in patients with excess visceral fat who have overt diabetes
mellitus, hypertension, dyslipidemia or MetS.
8–11 In addi-
tion, the present study suggests the possibility that the
decrease of adiponectin may begin at an early stage when
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Figure 3 Waist circumference and the serum adiponectin level. Gray bars
(left) show the waist circumference in men and black bars (right) show it in
women.
Table 2 The result of multivariable analysis of correlation between the
number of metabolic syndrome components and various parameters,
including adiponectin
B b P 95% CI
Lower Upper
Invariable  2.503 0.00  2.657  2.349
BMI 0.117 0.362 0.00 0.112 0.122
HOMA-R 0.249 0.226 0.00 0.234 0.263
Age (year) 0.015 0.164 0.00 0.014 0.016
Sex (female)  0.298  0.144 0.00  0.332  0.263
Uric acid (mgdl
 1) 0.081 0.110 0.00 0.07 0.091
Adiponectin (mgml
 1)  0.011  0.061 0.00  0.014  0.009
Cr  0.288  0.053 0.00  0.362  0.214
Smoking (yes) 0.069 0.028 0.00 0.041 0.097
Abbreviations: BMI, body mass index; CI, confidence interval; Cr, serum
creatinine; HOMA-IR, homeostasis model assessment-insulin resistance.
B, partial regression coefficient; b, standard partial regression coefficient;
P, significance probability. Objective variable, the number of metabolic
syndrome components stepwise multiple regression analysis.
Table 3 The result of multivariable analysis of the relationship between the
number of high normal components and other variables, including
adiponectin
B b P 95% CI
Lower Upper
Invariable  0.863 0.000  1.049  0.677
Age (year) 0.013 0.226 0.000 0.012 0.015
BMI 0.033 0.138 0.000 0.027 0.039
HOMA-R 0.131 0.126 0.000 0.108 0.154
Uric acid (mgdl
 1) 0.025 0.050 0.000 0.012 0.039
Sex (female)  0.066  0.050 0.001  0.106  0.026
Adiponectin (mgml
 1)  0.004  0.039 0.001  0.007 0.002
Smoking (yes)  0.051  0.030 0.005  0.086  0.016
Cr  0.091  0.027 0.033  0.175  0.007
Abbreviations: BMI, body mass index; CI, confidence interval; Cr, serum
creatinine; HOMA-IR, homeostasis model assessment-insulin resistance.
B, partial regression coefficient; b, standard partial regression coefficient;
P, significance probability. Objective variable: the number of metabolic
syndrome components stepwise multiple regression analysis.
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abnormalities, on the way to MetS.
Moreover, this study suggested that not only visceral fat
but also adiponectin itself can influence metabolic/physio-
logical factors, just as it has been reported that the decrease
of adiponectin increases the risk of type 2 diabetes mellitus,
8
hypertension,
9 dyslipidemia
10 and atherosclerotic diseases.
7
Therefore, the adiponectin level can be a reliable predictor of
the risk of cardiovascular and cerebrovascular disease in
people with borderline metabolic/physiological abnormal-
ities, as well as in those who have other obvious risk factors
like diabetes, hypertension, dyslipidemia or MetS.
In conclusion, we found that a decrease of circulating
adiponectin starts at a very early stage before the onset of
overt diabetes, hypertension, dyslipidemia or MetS. Accord-
ingly, in persons with borderline metabolic/physiological
abnormalities (as well as overt diseases), adiponectin is an
important biomarker for the risk of atherosclerotic disease
both independently and as a reflection of the accumulation
of visceral fat.
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